PF-07104091 as a Single Agent and in Combination Therapy

This is modestly more likely than not to produce a “positive” result because the study is fundamentally a safety and dose-finding program, not a high-bar efficacy trial. The primary endpoints are DLTs, treatment-emergent adverse events, lab abnormalities, and determination of MTD/RP2D—objective endpoints that an experienced sponsor can often complete successfully if the compound is pharmacologically workable. Pfizer’s operational strength and the trial being Active Not Recruiting near primary completion reduce the risk of pure execution failure. Still, conviction should stay limited. The population is broad and difficult: advanced or metastatic small cell lung, ovarian, and breast cancers, with both monotherapy and combination cohorts. That creates heterogeneity in tolerability and makes the overall narrative vulnerable to one weak or toxic cohort. The palbociclib-based combinations especially introduce plausible overlapping hematologic toxicity. Because the protocol emphasis is on safety/tolerability rather than a prespecified efficacy hurdle, YES has a slight edge, but only a modest one.

This is a Phase 1/2 dose-escalation safety study with primary endpoints focused on DLTs and TEAEs — not efficacy. For such studies, 'positive results' is ambiguous but typically means the drug demonstrated acceptable safety and identified a viable RP2D. Early data from ASCO 2023 showed PF-07104091 monotherapy was generally well-tolerated with a 61.5% DCR in breast cancer, suggesting safety endpoints could be met. However, several concerning factors lower probability: (1) Pfizer's own pipeline lists tegtociclib as still Phase 1 as of August 2025, not having advanced, (2) the palbociclib combination arms appear discontinued in favor of the atirmociclib combo in a separate trial, suggesting limited enthusiasm for these specific combinations, (3) monotherapy showed no activity in non-breast tumor types (SCLC, ovarian), and (4) Pfizer's strategic focus has shifted toward CDK4+CDK2 combinations rather than the arms in this trial. The mixed efficacy signals across multiple indications and the apparent deprioritization of some arms make a clear 'positive' readout uncertain. Modest safety success is likely, but limited efficacy signals create ambiguity.

This is a Phase 2 dose escalation/expansion trial for PF-07104091 across three solid tumor types. The primary endpoints focus on safety (DLTs, adverse events) and dose-finding (MTD/RP2D) rather than efficacy. Phase 2 safety trials have reasonable success rates when the drug's mechanism is sound and no red flags exist in preclinical/Phase 1 data. Pfizer's resources and execution capability support probability above coin-flip. However, combination therapy arms add complexity, and the trial spans multiple indications with different risk profiles. The 'Active Not Recruiting' status with past primary completion date suggests data is maturing. Given the safety-focused endpoints and standard Phase 2 success rates (50-60% for dose-finding), intrinsic YES odds are modestly above even.

This is a Phase 2 dose-finding and safety study for PF-07104091, a Pfizer asset, in advanced solid tumors. The primary endpoints are safety-focused: dose-limiting toxicities (DLTs) and adverse events. The question 'Will the results be positive?' is ambiguous but typically for a safety trial, 'positive' means establishing a safe recommended dose. Given Pfizer's operational strength and the trial's 'Active Not Recruiting' status near its completion date, it will likely complete and define a dose. However, the intrinsic probability of a definitively 'positive' outcome for efficacy is low, as this is not a pivotal efficacy study. The risk is that safety signals could preclude dose recommendation. The probability is weighted toward a successful safety readout but tempered by the endpoint's nature.

This Phase 2 trial evaluates PF-07104091 (CDK2 inhibitor) in advanced SCLC, ovarian, and breast cancers via monotherapy dose escalation/expansion and combinations with palbociclib-fulvestrant/letrozole. Primary endpoints focus on safety: DLTs in cycle 1 (Grade 3+ AEs), overall TEAEs/labs summarized by dose level up to ~2 years. Standard, objective safety metrics with high endpoint quality for dose-finding. Patient population is relapsed/refractory solid tumors with high unmet need; SCLC aggressive but responsive to novel targeted agents, ovarian/breast HR+ subsets familiar for CDK combos. No efficacy primaries, so 'positive results' hinges on identifying MTD/RP2D without prohibitive toxicity (>33% DLT typical threshold). Pfizer's execution strong (reputable sponsor, NCT04553133 active not recruiting, primary completion 2026-03-30 just passed). Prior Phase 1 data implied tolerable for escalation. Operational risks low: multi-arm design modular, allows arm-specific RP2D. Disclosure risk minimal as public filer with incentives for prompt topline. Historical dose-escalation success ~80% in similar oncology; combos additive tox but palbo standard tolerable. Intrinsic YES: tolerable profile enabling Phase 3 path.

The trial has already passed its primary completion date. The primary endpoint focuses on safety and tolerability (DLTs) rather than clinical efficacy. Given the status 'Active, not recruiting' and the sponsor's lack of a press release, the trial likely failed to meet efficacy targets or faced development hurdles. The primary outcome measures are safety-focused, which generally yields positive results, but the question implies a more holistic success. The lack of positive news flow suggests a low probability of a 'positive' result in terms of efficacy, but the safety data is likely acceptable. However, the market price of ~0.50 is efficient, reflecting the uncertainty. The probability of a strictly 'positive' result (efficacy) is lower than the market price suggests.

PF-07104091 is a Phase 2 CDK2 inhibitor in dose escalation/expansion for SCLC, ovarian and breast cancers. Primary endpoint focuses on safety/MTD determination rather than efficacy signals. The trial completed primary completion 3 days ago (March 30, 2026) with status 'Active Not Recruiting'—suggesting data lock may be imminent. Early-phase oncology trials with safety-primary endpoints have modest success rates (~30-40%) for ultimately positive readouts, especially in heavily pre-treated populations. CDK2 inhibitors face known tolerability challenges (myelosuppression, GI toxicity) that often limit dose escalation. No interim efficacy data has been disclosed. The combination arms with palbociclib add complexity but also prior validation. Disclosure risk is elevated given completion proximity.

This Phase 1/2a trial (NCT04553133) evaluates the safety, tolerability, and preliminary efficacy of the novel CDK2 inhibitor PF-07104091, primarily seeking to identify the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for both monotherapy and various combinations. The trial's primary endpoints are explicitly centered on safety and dose-finding. At ASCO 2023, Pfizer presented highly encouraging interim dose-escalation results. The monotherapy arm successfully identified an MTD of 300 mg BID, which was selected as the recommended dose for expansion. Furthermore, the drug demonstrated a manageable safety profile and achieved a 61.5% disease control rate in heavily pretreated HR+/HER2- metastatic breast cancer patients. While Pfizer discontinued the specific combination arm with palbociclib (Ibrance) back in late 2022, the company continued evaluating other combinations and the monotherapy expansions. Crucially, the continued viability of PF-07104091 is evidenced by Pfizer's ongoing pipeline support, including the initiation and recent completion of a dedicated Phase 1 ADME study (NCT07127770) in late 2025, as well as separate trials exploring combinations with their next-generation CDK4 inhibitor atirmociclib. Because the core dose-finding objectives were met and the asset continues advancing in Pfizer's clinical pipeline, the final trial results are highly likely to be considered positive.

The trial is in Phase 2, actively recruiting, with a focus on assessing the safety and tolerability of PF-07104091. The primary endpoint involves evaluating dose-limiting toxicities and adverse events, which is a common approach for early-stage cancer treatments. While the indication includes aggressive cancers like small cell lung cancer, ovarian cancer, and breast cancer, the current status is 'Active Not Recruiting', suggesting that the trial is still in its early stages and hasn't yet reported efficacy results. Given these factors, a 45% probability of a positive outcome seems reasonable, reflecting moderate uncertainty.